Resource Summary Report

Generated by NIF on Sep 11, 2026

Phospho-4E-BP1 (Thr37/46) Antibody

RRID:AB_330985
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9459, RRID:AB_330985

Antibody Information

URL: http://antibodyregistry.org/AB_330985

Proper Citation: Cell Signaling Technology Cat# 9459, RRID:AB_330985

Target Antigen: Phospho-4E-BP1 (Thr37/46)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10078082, AB_10078672, AB_2262165, AB_330985. Info: Used By NYUIHC-581.
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-4E-BP1 (Thr37/46) Antibody

Description: This polyclonal targets Phospho-4E-BP1 (Thr37/46)

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_330985

Vendor: Cell Signaling Technology

Catalog Number: 9459

Record Creation Time: 20231110T081341+0000

Record Last Update: 20260831T212527+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for Phospho-4E-BP1 (Thr37/46) Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Mahmoud A, et al. (2026) An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis. Developmental cell, 61(6), 1289.

Smith MJ, et al. (2026) Persistent Human Quadriceps Muscle Volume Deficits Following ACL Reconstruction Are Associated With No Detectable Between-Leg Differences in Vastus Lateralis Muscle Signaling at Rest or Immediately Following Resistance Exercise. Scandinavian journal of medicine & science in sports, 36(7), e70343.

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. Cell reports, 45(7), 117559.

Juric D, et al. (2026) PI3K? Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 56.

Choi YK, et al. (2026) The REDD1-NF-?B-miRNAs-eNOS/SIRT1 axis mediates obesity-induced endothelial cell senescence and hypertension. Nature communications, 17(1).

Li G, et al. (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. Cell metabolism, 38(1), 174.

Park SJ, et al. (2026) Mechanism by which a linoleic acid metabolite suppresses cancer cell growth by inhibiting mTOR. Cell chemical biology, 33(5), 637.

Bakhmet EI, et al. (2026) PCBP1 orchestrates amino acid metabolism burst during the naïve-to-primed pluripotency transition. Stem cell reports, 21(7), 102950.

Koshizuka K, et al. (2025) Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. Cancer research, 85(16), 3032.

Mahmoud A, et al. (2025) Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer. bioRxiv : the preprint server for biology.

Middleton G, et al. (2025) A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer. NPJ precision oncology, 9(1), 67.

Iwamoto Y, et al. (2025) Lactoferrin attenuates renal fibrosis and uremic sarcopenia in a mouse model of adenine-induced chronic kidney disease. The Journal of nutritional biochemistry, 146, 110039.

Burgmer S, et al. (2025) Endosymbiont control through non-canonical immune signaling and gut metabolic remodeling. Cell reports, 44(6), 115811.

Thalalla Gamage S, et al. (2025) Transfer RNA acetylation regulates in vivo mammalian stress signaling. Science advances, 11(12), eads2923.

Liu X, et al. (2025) Discovery, delineation, and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome. Cell reports. Medicine, 102531.

Wang X, et al. (2024) The ATAC complex represses the transcriptional program of the autophagy-lysosome pathway via its E3 ubiquitin ligase activity. Cell reports, 43(12), 115033.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC ? in lung adenocarcinoma. Cell reports, 43(12), 115026.

Thapa N, et al. (2024) A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism. Cell reports, 43(5), 114119.

Unachukwu U, et al. (2023) Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis. Molecular cancer therapeutics, 22(7), 844.

Festa BP, et al. (2023) Microglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration. Neuron, 111(13), 2021.